STOCK TITAN

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Guardant Health (GH) Form 4: Director Steve E. Krognes reported the automatic conversion of 154 restricted stock units (RSUs) into an equal number of common shares on 07/31/2025 (transaction code “M”). No shares were sold. The RSUs stem from an August 9 2022 grant that vested 25 % on 06/30/2023; the remaining 75 % continue to vest in equal monthly installments through mid-2026.

Following the conversion, Krognes now holds 17,973 shares directly and retains 1,698 un-settled RSUs. The transaction was priced at $0, indicating a standard equity award settlement rather than an open-market purchase. Ownership structure remains direct, and no 10b5-1 plan was indicated.

Guardant Health (GH) Modulo 4: Il direttore Steve E. Krognes ha segnalato la conversione automatica di 154 unità di azioni vincolate (RSU) in un numero equivalente di azioni ordinarie il 31/07/2025 (codice transazione “M”). Nessuna azione è stata venduta. Le RSU derivano da una concessione del 9 agosto 2022 che è maturata per il 25% al 30/06/2023; il restante 75% continua a maturare in rate mensili uguali fino a metà 2026.

Dopo la conversione, Krognes detiene ora 17.973 azioni direttamente e mantiene 1.698 RSU non ancora regolate. La transazione è stata valutata a 0$, indicando un normale regolamento di azioni come premio azionario e non un acquisto sul mercato aperto. La struttura di proprietà rimane diretta e non è stato indicato alcun piano 10b5-1.

Guardant Health (GH) Formulario 4: El director Steve E. Krognes informó la conversión automática de 154 unidades de acciones restringidas (RSU) en un número igual de acciones ordinarias el 31/07/2025 (código de transacción “M”). No se vendieron acciones. Las RSU provienen de una concesión del 9 de agosto de 2022 que se consolidó en un 25% el 30/06/2023; el 75% restante continúa consolidándose en cuotas mensuales iguales hasta mediados de 2026.

Tras la conversión, Krognes ahora posee 17,973 acciones directamente y retiene 1,698 RSU pendientes de liquidación. La transacción se valoró en $0, lo que indica un ajuste estándar de premio en acciones en lugar de una compra en el mercado abierto. La estructura de propiedad sigue siendo directa y no se indicó ningún plan 10b5-1.

Guardant Health (GH) Form 4: 이사 Steve E. Krognes는 2025년 7월 31일에 154개의 제한 주식 단위(RSU)가 동일한 수의 보통주로 자동 전환되었음을 보고했습니다(거래 코드 “M”). 주식은 판매되지 않았습니다. 이 RSU는 2022년 8월 9일 부여된 것으로, 2023년 6월 30일에 25%가 베스팅되었으며 나머지 75%는 2026년 중반까지 매월 동일한 비율로 베스팅되고 있습니다.

전환 후 Krognes는 17,973주를 직접 보유하고 있으며, 아직 정산되지 않은 RSU 1,698주를 보유하고 있습니다. 거래 가격은 0달러로, 이는 공개 시장에서의 구매가 아닌 표준 주식 보상 정산임을 나타냅니다. 소유 구조는 직접 소유 상태이며, 10b5-1 계획은 명시되지 않았습니다.

Guardant Health (GH) Formulaire 4 : Le directeur Steve E. Krognes a déclaré la conversion automatique de 154 unités d’actions restreintes (RSU) en un nombre égal d’actions ordinaires le 31/07/2025 (code transaction « M »). Aucune action n’a été vendue. Les RSU proviennent d’une attribution du 9 août 2022, dont 25 % ont été acquises au 30/06/2023 ; les 75 % restants continuent de s’acquérir par versements mensuels égaux jusqu’à la mi-2026.

Après la conversion, Krognes détient désormais 17 973 actions directement et conserve 1 698 RSU non encore réglées. La transaction a été valorisée à 0 $, indiquant un règlement standard d’attribution d’actions plutôt qu’un achat sur le marché ouvert. La structure de propriété reste directe et aucun plan 10b5-1 n’a été indiqué.

Guardant Health (GH) Formular 4: Direktor Steve E. Krognes meldete die automatische Umwandlung von 154 Restricted Stock Units (RSUs) in eine gleiche Anzahl von Stammaktien am 31.07.2025 (Transaktionscode „M“). Es wurden keine Aktien verkauft. Die RSUs stammen aus einer Zuteilung vom 9. August 2022, von der 25 % am 30.06.2023 fällig wurden; die verbleibenden 75 % werden weiterhin in gleichen monatlichen Raten bis Mitte 2026 fällig.

Nach der Umwandlung hält Krognes nun 17.973 Aktien direkt und behält 1.698 noch nicht abgewickelte RSUs. Die Transaktion wurde mit 0 $ bewertet, was auf eine Standard-Abwicklung einer Aktienprämie und keinen Kauf am offenen Markt hinweist. Die Eigentümerstruktur bleibt direkt, und ein 10b5-1-Plan wurde nicht angegeben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small RSU vesting; negligible market impact.

The filing shows routine settlement of 154 RSUs from a 2022 grant. No cash purchase, no sales, and ownership rises marginally to 17,973 shares plus 1,698 RSUs. Because the quantity is immaterial relative to GH’s 106 M share float, signal value for investors is minimal. It does, however, reaffirm ongoing equity-based compensation alignment for an outside director, which is standard governance practice rather than a directional bet.

Guardant Health (GH) Modulo 4: Il direttore Steve E. Krognes ha segnalato la conversione automatica di 154 unità di azioni vincolate (RSU) in un numero equivalente di azioni ordinarie il 31/07/2025 (codice transazione “M”). Nessuna azione è stata venduta. Le RSU derivano da una concessione del 9 agosto 2022 che è maturata per il 25% al 30/06/2023; il restante 75% continua a maturare in rate mensili uguali fino a metà 2026.

Dopo la conversione, Krognes detiene ora 17.973 azioni direttamente e mantiene 1.698 RSU non ancora regolate. La transazione è stata valutata a 0$, indicando un normale regolamento di azioni come premio azionario e non un acquisto sul mercato aperto. La struttura di proprietà rimane diretta e non è stato indicato alcun piano 10b5-1.

Guardant Health (GH) Formulario 4: El director Steve E. Krognes informó la conversión automática de 154 unidades de acciones restringidas (RSU) en un número igual de acciones ordinarias el 31/07/2025 (código de transacción “M”). No se vendieron acciones. Las RSU provienen de una concesión del 9 de agosto de 2022 que se consolidó en un 25% el 30/06/2023; el 75% restante continúa consolidándose en cuotas mensuales iguales hasta mediados de 2026.

Tras la conversión, Krognes ahora posee 17,973 acciones directamente y retiene 1,698 RSU pendientes de liquidación. La transacción se valoró en $0, lo que indica un ajuste estándar de premio en acciones en lugar de una compra en el mercado abierto. La estructura de propiedad sigue siendo directa y no se indicó ningún plan 10b5-1.

Guardant Health (GH) Form 4: 이사 Steve E. Krognes는 2025년 7월 31일에 154개의 제한 주식 단위(RSU)가 동일한 수의 보통주로 자동 전환되었음을 보고했습니다(거래 코드 “M”). 주식은 판매되지 않았습니다. 이 RSU는 2022년 8월 9일 부여된 것으로, 2023년 6월 30일에 25%가 베스팅되었으며 나머지 75%는 2026년 중반까지 매월 동일한 비율로 베스팅되고 있습니다.

전환 후 Krognes는 17,973주를 직접 보유하고 있으며, 아직 정산되지 않은 RSU 1,698주를 보유하고 있습니다. 거래 가격은 0달러로, 이는 공개 시장에서의 구매가 아닌 표준 주식 보상 정산임을 나타냅니다. 소유 구조는 직접 소유 상태이며, 10b5-1 계획은 명시되지 않았습니다.

Guardant Health (GH) Formulaire 4 : Le directeur Steve E. Krognes a déclaré la conversion automatique de 154 unités d’actions restreintes (RSU) en un nombre égal d’actions ordinaires le 31/07/2025 (code transaction « M »). Aucune action n’a été vendue. Les RSU proviennent d’une attribution du 9 août 2022, dont 25 % ont été acquises au 30/06/2023 ; les 75 % restants continuent de s’acquérir par versements mensuels égaux jusqu’à la mi-2026.

Après la conversion, Krognes détient désormais 17 973 actions directement et conserve 1 698 RSU non encore réglées. La transaction a été valorisée à 0 $, indiquant un règlement standard d’attribution d’actions plutôt qu’un achat sur le marché ouvert. La structure de propriété reste directe et aucun plan 10b5-1 n’a été indiqué.

Guardant Health (GH) Formular 4: Direktor Steve E. Krognes meldete die automatische Umwandlung von 154 Restricted Stock Units (RSUs) in eine gleiche Anzahl von Stammaktien am 31.07.2025 (Transaktionscode „M“). Es wurden keine Aktien verkauft. Die RSUs stammen aus einer Zuteilung vom 9. August 2022, von der 25 % am 30.06.2023 fällig wurden; die verbleibenden 75 % werden weiterhin in gleichen monatlichen Raten bis Mitte 2026 fällig.

Nach der Umwandlung hält Krognes nun 17.973 Aktien direkt und behält 1.698 noch nicht abgewickelte RSUs. Die Transaktion wurde mit 0 $ bewertet, was auf eine Standard-Abwicklung einer Aktienprämie und keinen Kauf am offenen Markt hinweist. Die Eigentümerstruktur bleibt direkt, und ein 10b5-1-Plan wurde nicht angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krognes Steve E.

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/31/2025 M 154 A $0 17,973 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 07/31/2025 M 154 (1) (2) Common Stock 154 $0 1,698 D
Explanation of Responses:
1. This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award `on June 30, 2023. The remaining 75% of the shares subject to such award vest in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.
2. Not applicable for Restricted Stock Units.
Remarks:
/s/ John Saia, as attorney-in-fact for Steve Krognes 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Guardant Health (GH) shares did Steve Krognes acquire?

He acquired 154 common shares through the vesting of restricted stock units.

What is Steve Krognes’ total direct share ownership after the transaction?

Direct ownership increased to 17,973 GH shares.

Were any shares sold in this Form 4 filing?

No. The filing reports only the acquisition of shares via RSU conversion; no sales occurred.

What is the origin of the RSUs that vested on 07/31/2025?

They are part of an August 9 2022 grant that vests 25 % on 06/30/2023 and monthly thereafter over three years.

Does the filing reference a Rule 10b5-1 trading plan?

No, the indicated 10b5-1 checkbox was not marked.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

5.17B
118.23M
4.5%
99.25%
7.7%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO